Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: Cardiac responses and overall effects Academic Article uri icon

Overview

MeSH Major

  • Amyloidosis
  • Antineoplastic Agents
  • Boronic Acids
  • Heart Diseases
  • Pyrazines

abstract

  • AL is frequently rapidly progressive; in these patients who had relapsed or progressed following previous conventional therapies, these results suggest that bortezomib may slow the progression of cardiac amyloid with limited toxicity.

publication date

  • November 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1093/qjmed/hcr105

PubMed ID

  • 21752867

Additional Document Info

start page

  • 957

end page

  • 70

volume

  • 104

number

  • 11